WoundSource Section Logos - White Papers

Clinical Results Managing Incontinence-Associated Dermatitis (IAD) and Reducing Clinical Redness with Zinc Formula Containing Fecal Enzyme Inhibition Cream

Clinical Results Managing IAD and Reducing Clinical Redness
If you requested a sample, please provide your mailing address
 

Incontinence-associated dermatitis (IAD) is a significant concern for incontinent older adults living in skilled nursing facilities. Complications of IAD include pressure ulcers/injuries and infection. A proactive approach to IAD prevention and management includes meticulous, evidence-based skin care.

This illustrated and referenced guide gives an overview of the epidemiology, costs, and principles of managing IAD. It then describes a recent clinical study of an innovative Balmex cream that combines zinc oxide with fecal enzyme inhibition (FEI) technology. Study results show that this product can help reduce skin redness, a cardinal sign of inflammation and a precursor to skin breakdown.

Health care professionals, especially those caring for facility residents at risk of IAD and its complications, will be encouraged by the Balmex clinical study results, which show efficacy in reducing the inflammatory effects of skin exposure to moisture.

This well-referenced guide contains useful information on the following topics:

Epidemiology of IAD
Complications of IAD
Financial costs of IAD
Management principles of IAD
Benefits of zinc oxide cream with addition of FEI
Mechanism of action of Balmex zinc cream with FEI technology
Clinical study of Balmex zinc cream with FEI technology
Study implications for IAD management

This paper is written for wound care clinicians and purchasing directors with an interest in product solutions. This paper was developed by an independent third party.

Sponsored by Balmex

Incontinence-associated dermatitis (IAD) is a significant concern for incontinent older adults living in skilled nursing facilities. Complications of IAD include pressure ulcers/injuries and infection. A proactive approach to IAD prevention and management includes meticulous, evidence-based skin care.

This illustrated and referenced guide gives an overview of the epidemiology, costs, and principles of managing IAD. It then describes a recent clinical study of an innovative Balmex cream that combines zinc oxide with fecal enzyme inhibition (FEI) technology. Study results show that this product can help reduce skin redness, a cardinal sign of inflammation and a precursor to skin breakdown.

Health care professionals, especially those caring for facility residents at risk of IAD and its complications, will be encouraged by the Balmex clinical study results, which show efficacy in reducing the inflammatory effects of skin exposure to moisture.

This guide covers the following topics:

Epidemiology of IAD
Complications of IAD
Financial costs of IAD
Management principles of IAD
Benefits of zinc oxide cream with addition of FEI
Mechanism of action of Balmex zinc cream with FEI technology
Clinical study of Balmex zinc cream with FEI technology
Study implications for IAD management

This paper is written for wound care clinicians and purchasing directors with an interest in product solutions. This paper was developed by an independent third party.

Sponsored by Balmex

WoundSource
The World’s Definitive Source for Wound Care & Product Information